All blogs
    Biotech

    How do biotech and life sciences startups get press coverage?

    Biotech venture funding hit 9.1 billion dollars in the first half of 2026, the highest since 2022. How to pitch that news without the kind of overstated claim that has triggered SEC enforcement action before.

    A doctor in a white coat holding a stethoscope

    This article covers PR and communications strategy only. It contains no medical, legal or financial advice, and nothing here should be read as such. A biotech company's own regulatory counsel and medical affairs team should review any specific claim, especially anything about trial results, before it goes out.

    By pitching a real event, a funding round, a trial readout, a regulatory filing, with language that matches the underlying data exactly, and by routing anything that touches clinical results through legal and medical affairs before it reaches a reporter or a wire. Biotech is one of the few beats in PR where a badly worded press release doesn't just fail to land. It can draw a federal enforcement action. Here is how the beat actually works, and where companies get into trouble.

    What's actually happening in biotech funding right now?

    A rebound built on fewer, much bigger rounds. BioPharma Dive's tracking of venture data found that at least 68 biotech companies raised more than 9.1 billion dollars in venture funding between January and June 2026, the highest first-half total since 2022. About 76 percent of that money came from megarounds of 100 million dollars or more, and a single 2.1 billion dollar round for Isomorphic Labs accounted for a meaningful share of the total on its own. PitchBook analyst Ben Zercher told BioPharma Dive that venture capital had "continued to go strong" despite a threatened US crackdown on Chinese drug asset investments and ongoing turmoil at the FDA.

    The same data shows where the money is concentrating: 42 of the roughly 68 rounds, about two-thirds, went to companies with a drug candidate already in human testing. Immune and cancer-focused drugmakers accounted for more than 40 percent of rounds, while cell and gene therapy stayed in a multi-year slump. Two Ernst & Young partners quoted in the same piece, Ashwin Singhania and Doreen Levine, both described investors as having capital available but being selective, particularly with seed-stage and first-time founders. That matters for pitching: a company at the earlier, harder-funded end of that spectrum has more reason to use press coverage to build credibility with investors, not just customers.

    9Bdollars biotechs raised in venture funding in H1 2026, the highest first half since 2022
    76%of that funding that came from megarounds of 100 million dollars or more
    200Kdollar penalty TherapeuticsMD paid for a Regulation FD violation over FDA meeting details

    Source: BioPharma Dive's H1 2026 venture funding data and the SEC's TherapeuticsMD enforcement order, both linked in the article.

    Why can't a biotech startup just say whatever it wants about a trial result?

    Because for a public company, selectively sharing material information is a securities law violation, not just bad practice. The SEC's Regulation FD bars companies from disclosing material nonpublic information to analysts or investors without making the same information public at the same time. The SEC's own enforcement order against TherapeuticsMD shows what this looks like in practice: in June 2017, the company privately told sell-side analysts that an FDA meeting had been "very positive and productive," and its stock closed up 19.4 percent the next day with no public disclosure of what had been said. A second selective disclosure followed in July, when executives shared undisclosed details about a regulatory setback with analysts before the market opened. TherapeuticsMD settled without admitting or denying the SEC's findings, paying a 200,000 dollar penalty and agreeing to a cease-and-desist order.

    A private biotech doesn't answer to Regulation FD the same way, but the underlying discipline still applies to how any trial update gets written and who sees it first. If an investor, a journalist and a prospective partner all need to hear about the same result, they should all be hearing the same claim, worded the same way, at the same time.

    A scientific publication and a company press release are not two separate announcements you can time however you like.

    Why does embargo culture matter so much in this industry?

    Because the most credible outlets in biotech, STAT News among them, draw heavily on findings first published in peer-reviewed journals, and those journals have their own rules about when a company can talk about its own data publicly. The practice traces back to a policy the New England Journal of Medicine adopted under editor Franz Ingelfinger in 1969, later nicknamed the Ingelfinger Rule, which held that NEJM would not publish research that had already been reported elsewhere. Most major journals that publish clinical research, including Nature and Science, have adopted variants of the same approach: authors agree not to discuss their own unpublished findings with media until an embargo tied to the paper's publication lifts.

    For a biotech communications team, that means a scientific publication and a company press release are not two separate announcements you can time however you like. If a company's own trial data is headed for a peer-reviewed paper, going to press before the embargo lifts can jeopardize the publication itself, not just annoy an editor. How to write a press release covers the format question; for a biotech company, the harder question is almost always timing, not wording.

    A federal one, separate from anything a journal requires. Under the FDAAA 801 final rule, sponsors of "applicable clinical trials," most interventional trials of drugs, biologics and devices beyond early feasibility studies, must submit summary results to ClinicalTrials.gov within 12 months of a trial's primary completion date, regardless of whether the result was positive, negative, or the trial was stopped early. This is a compliance obligation that exists independently of any press strategy. A company that is selective in what it tells reporters about a trial, while the full results are due to post publicly on a federal registry within a year, is setting up a gap that a reporter, or a short seller, can and will point to later.

    What happens when a company's language gets ahead of its data?

    The claim becomes the story, and not in the way the company wanted. A pattern shows up repeatedly in SEC and FDA enforcement history: a company's public description of a trial outcome, an FDA meeting, or a regulatory interaction drifts further from the underlying data than the data supports, and the gap eventually surfaces, usually through an analyst question, a follow-up filing, or a later readout that contradicts the earlier framing. The fix is mechanical, not creative: every claim about a trial result in a press release should trace back to a specific number in the data, stated at the same level of confidence the data actually supports, with any caveats about sample size or subgroup analysis included rather than dropped for brevity.

    This is also where a funding or partnership announcement is a much safer place to build visibility than a trial result. How to announce a funding round and how to announce a partnership both cover hooks that carry real news value without touching clinical claims at all, and for an earlier-stage biotech trying to build investor and media credibility before its first major readout, that is often the more useful place to start.

    What should a biotech company actually do before it talks to a reporter?

    Put the claim and the source data next to each other before anyone outside the company sees either one. Any statement about efficacy, safety, or regulatory status should be checked by the people who generated the underlying data and by legal counsel, not rewritten by whoever is fastest to draft a release. For a public company, that review has to confirm the statement doesn't selectively disclose anything material that hasn't already been filed or published. For a private company racing toward its first major trial readout, the same review protects the thing that is often more fragile than any single data point: the credibility to be believed the next time there's news.

    The direct answer, for anyone who read this far

    Pitch real events, funding, partnerships, regulatory filings, trial readouts, state every data-backed claim at the confidence level the data actually supports, and get legal and medical affairs to check any clinical statement before a reporter sees it. If you want help building a biotech communications program that survives that scrutiny, get in touch.

    Written by Womedia Team

    White Ocean Media. Related service: Press Release Distribution